Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 101

1.

PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors.

Gebreyohannes YK, Burton EA, Wozniak A, Matusow B, Habets G, Wellens J, Cornillie J, Lin J, Nespi M, Wu G, Zhang C, Bollag G, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Exp Med. 2018 Dec 6. doi: 10.1007/s10238-018-0541-2. [Epub ahead of print]

PMID:
30523507
2.

Defense responses of Thuja orientalis to infestation of anholocyclic species aphid Cinara tujafilina.

Durak R, Bednarski W, Formela-Luboińska M, Woźniak A, Borowiak-Sobkowiak B, Durak T, Dembczyński R, Morkunas I.

J Plant Physiol. 2019 Jan;232:160-170. doi: 10.1016/j.jplph.2018.11.018. Epub 2018 Nov 22.

PMID:
30537603
3.

Anagrelide for Gastrointestinal Stromal Tumor.

Pulkka OP, Gebreyohannes YK, Wozniak A, Mpindi JP, Tynninen O, Icay K, Cervera A, Keskitalo S, Murumägi A, Kulesskiy E, Laaksonen M, Wennerberg K, Varjosalo M, Laakkonen P, Lehtonen R, Hautaniemi S, Kallioniemi O, Schöffski P, Sihto H, Joensuu H.

Clin Cancer Res. 2018 Dec 7. doi: 10.1158/1078-0432.CCR-18-0815. [Epub ahead of print]

PMID:
30530703
4.

Rapid Weight Loss and Dietary Inadequacies among Martial Arts Practitioners from Poland.

Anyżewska A, Dzierżanowski I, Woźniak A, Leonkiewicz M, Wawrzyniak A.

Int J Environ Res Public Health. 2018 Nov 6;15(11). pii: E2476. doi: 10.3390/ijerph15112476.

5.

Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.

Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, Evans E, Gardino AK, Lengauer C, Debiec-Rychter M, Sciot R, Schöffski P.

Clin Cancer Res. 2019 Jan 15;25(2):609-618. doi: 10.1158/1078-0432.CCR-18-1858. Epub 2018 Oct 1.

PMID:
30274985
6.

The Role of Heavy Metals in Plant Response to Biotic Stress.

Morkunas I, Woźniak A, Mai VC, Rucińska-Sobkowiak R, Jeandet P.

Molecules. 2018 Sep 11;23(9). pii: E2320. doi: 10.3390/molecules23092320. Review.

7.

Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.

Schöffski P, Sufliarsky J, Gelderblom H, Blay JY, Strauss SJ, Stacchiotti S, Rutkowski P, Lindner LH, Leahy MG, Italiano A, Isambert N, Debiec-Rychter M, Sciot R, Van Cann T, Marréaud S, Nzokirantevye A, Collette S, Wozniak A.

Lancet Respir Med. 2018 Jun;6(6):431-441. doi: 10.1016/S2213-2600(18)30116-4. Epub 2018 Apr 15.

PMID:
29669701
8.

The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.

Schöffski P, Wozniak A, Leahy MG, Aamdal S, Rutkowski P, Bauer S, Richter S, Grünwald V, Debiec-Rychter M, Sciot R, Geoerger B, Marréaud S, Collette S, Nzokirantevye A, Strauss SJ.

Eur J Cancer. 2018 May;94:156-167. doi: 10.1016/j.ejca.2018.02.011. Epub 2018 Mar 20.

PMID:
29567632
9.

Retrospective Analysis of Outcome of Patients with Metastatic Leiomyosarcoma in a Tertiary Referral Center.

van Cann T, Cornillie J, Wozniak A, Debiec-Rychter M, Sciot R, Hompes D, Vergote I, Schöffski P.

Oncol Res Treat. 2018;41(4):206-213. doi: 10.1159/000486419. Epub 2018 Mar 23.

PMID:
29562223
10.

Polymorphisms in the Von Hippel-Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors.

Verbiest A, Lambrechts D, Van Brussel T, Couchy G, Wozniak A, Méjean A, Lerut E, Oudard S, Verkarre V, Job S, de Reynies A, Machiels JP, Patard JJ, Zucman-Rossi J, Beuselinck B.

Clin Genitourin Cancer. 2018 Aug;16(4):266-273. doi: 10.1016/j.clgc.2018.01.013. Epub 2018 Feb 5.

PMID:
29503246
11.

Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.

Verbiest A, Couchy G, Job S, Caruana L, Lerut E, Oyen R, de Reyniès A, Tosco L, Joniau S, Van Poppel H, Van Raemdonck D, Van Den Eynde K, Wozniak A, Zucman-Rossi J, Beuselinck B.

Eur Urol. 2018 Oct;74(4):474-480. doi: 10.1016/j.eururo.2018.01.042. Epub 2018 Feb 17.

PMID:
29463434
12.

Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis.

Waligora M, Bala MM, Koperny M, Wasylewski MT, Strzebonska K, Jaeschke RR, Wozniak A, Piasecki J, Sliwka A, Mitus JW, Polak M, Nowis D, Fergusson D, Kimmelman J.

PLoS Med. 2018 Feb 20;15(2):e1002505. doi: 10.1371/journal.pmed.1002505. eCollection 2018 Feb. Review.

13.

Adherence to nutrition guidelines in patients with cardiovascular diseases (CVD) as a secondary prevention

Woźniak A, Krótki M, Anyżewska A, Górnicka M, Wawrzyniak A.

Rocz Panstw Zakl Hig. 2017;68(4):401-407.

14.

Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting.

Verbiest A, Couchy G, Job S, Zucman-Rossi J, Caruana L, Lerut E, Oyen R, de Reyniès A, Laguerre B, Rioux-Leclercq N, Wozniak A, Joniau S, Van Poppel H, Van Den Eynde K, Beuselinck B.

Clin Genitourin Cancer. 2018 Jun;16(3):e605-e612. doi: 10.1016/j.clgc.2017.10.017. Epub 2017 Nov 7.

PMID:
29239846
15.

Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.

Schöffski P, Wozniak A, Escudier B, Rutkowski P, Anthoney A, Bauer S, Sufliarsky J, van Herpen C, Lindner LH, Grünwald V, Zakotnik B, Lerut E, Debiec-Rychter M, Marréaud S, Lia M, Raveloarivahy T, Collette S, Albiges L.

Eur J Cancer. 2017 Dec;87:147-163. doi: 10.1016/j.ejca.2017.10.014. Epub 2017 Nov 14.

PMID:
29149761
16.

Primary myxoid mesenchymal tumour with intracranial location: report of a case with a EWSR1-ATF1 fusion.

Sciot R, Jacobs S, Calenbergh FV, Demaerel P, Wozniak A, Debiec-Rychter M.

Histopathology. 2018 Apr;72(5):880-883. doi: 10.1111/his.13437. Epub 2018 Jan 11. No abstract available.

PMID:
29143432
17.

New targets and therapies for gastrointestinal stromal tumors.

Wozniak A, Gebreyohannes YK, Debiec-Rychter M, Schöffski P.

Expert Rev Anticancer Ther. 2017 Dec;17(12):1117-1129. doi: 10.1080/14737140.2017.1400386. Review.

PMID:
29110548
18.

A precision therapy against cancers driven by KIT/PDGFRA mutations.

Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A, Zhu XJ, Schmidt-Kittler O, Wilson D, Wilson K, DiPietro L, Zhang Y, Brooijmans N, LaBranche TP, Wozniak A, Gebreyohannes YK, Schöffski P, Heinrich MC, DeAngelo DJ, Miller S, Wolf B, Kohl N, Guzi T, Lydon N, Boral A, Lengauer C.

Sci Transl Med. 2017 Nov 1;9(414). pii: eaao1690. doi: 10.1126/scitranslmed.aao1690.

PMID:
29093181
19.

The Influence of Lead on Generation of Signalling Molecules and Accumulation of Flavonoids in Pea Seedlings in Response to Pea Aphid Infestation.

Woźniak A, Drzewiecka K, Kęsy J, Marczak Ł, Narożna D, Grobela M, Motała R, Bocianowski J, Morkunas I.

Molecules. 2017 Aug 24;22(9). pii: E1404. doi: 10.3390/molecules22091404.

20.

Assessment of differences in nutrients consumption in women diagnosed with osteoporosis as compared to a healthy control group

Wawrzyniak A, Klimczyk P, Woźniak A, Anyżewska A, Leonkiewicz M.

Rocz Panstw Zakl Hig. 2017;68(2):143-149.

Supplemental Content

Loading ...
Support Center